Real-world feasibility of first-line palbociclib for hormone receptor-positive HER2-negative locally advanced/metastatic breast cancer in women aged 70 years and older - final results of the endocrine-sensitive cohort in the French prospective non-interventional PalomAGE study.

Carola E, Caillet P, Falandry C, Tassy L, Paillaud E, Pulido M, Rochette de Lempdes G, Bringuier M, Jovenin N, Boudrant A, Grosjean J, Chakiba-Brugere C, Guillem O, Hardy Bessard AC, Orfeuvre H, Legouffe E, Brault Y, Chen C, Coumert A, Decrop M, Bouteiller F, Brain E

Open source

DOI: 10.1016/j.breast.2026.104879
Published: 2026 Oct
Container: Breast (Edinburgh, Scotland)
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.breast.2026.104879,
  title = {Real-world feasibility of first-line palbociclib for hormone receptor-positive HER2-negative locally advanced/metastatic breast cancer in women aged 70 years and older - final results of the endocrine-sensitive cohort in the French prospective non-interventional PalomAGE study.},
  author = {Carola E and Caillet P and Falandry C and Tassy L and Paillaud E and Pulido M and Rochette de Lempdes G and Bringuier M and Jovenin N and Boudrant A and Grosjean J and Chakiba-Brugere C and Guillem O and Hardy Bessard AC and Orfeuvre H and Legouffe E and Brault Y and Chen C and Coumert A and Decrop M and Bouteiller F and Brain E},
  year = {2026},
  journal = {Breast (Edinburgh, Scotland)},
  doi = {10.1016/j.breast.2026.104879},
  url = {https://doi.org/10.1016/j.breast.2026.104879}
}

RIS

TY  - JOUR
TI  - Real-world feasibility of first-line palbociclib for hormone receptor-positive HER2-negative locally advanced/metastatic breast cancer in women aged 70 years and older - final results of the endocrine-sensitive cohort in the French prospective non-interventional PalomAGE study.
AU  - Carola E
AU  - Caillet P
AU  - Falandry C
AU  - Tassy L
AU  - Paillaud E
AU  - Pulido M
AU  - Rochette de Lempdes G
AU  - Bringuier M
AU  - Jovenin N
AU  - Boudrant A
AU  - Grosjean J
AU  - Chakiba-Brugere C
AU  - Guillem O
AU  - Hardy Bessard AC
AU  - Orfeuvre H
AU  - Legouffe E
AU  - Brault Y
AU  - Chen C
AU  - Coumert A
AU  - Decrop M
AU  - Bouteiller F
AU  - Brain E
PY  - 2026
JO  - Breast (Edinburgh, Scotland)
DO  - 10.1016/j.breast.2026.104879
UR  - https://doi.org/10.1016/j.breast.2026.104879
ER  -

APA

E, C., P, C., C, F., L, T., E, P., M, P., G, R. D. L., M, B., N, J., A, B., J, G., C, C., O, G., AC, H. B., H, O., E, L., Y, B., C, C., A, C., M, D., F, B., & E, B. (2026). Real-world feasibility of first-line palbociclib for hormone receptor-positive HER2-negative locally advanced/metastatic breast cancer in women aged 70 years and older - final results of the endocrine-sensitive cohort in the French prospective non-interventional PalomAGE study.. Breast (Edinburgh, Scotland). https://doi.org/10.1016/j.breast.2026.104879

Source records

pubmed · retrieved 2026-09-25T10:51:20.841Z